Machine learning of 701 Anti-Synthetase (Anti-Jo1, -PL7, -PL12, -EJ) identifies 3 Endotypes,independent Ab specificity #1 (24%) w/ RP-ILD & high mortality #2 (14%) dermatomyositis, intermediate prognosis #3 (62%) arthritis & mechanics hands, good prognosis https://t.co/y9LMCfMIgN https://t.co/y0MbYlbbrV

Many with PsA Fail to Achieve Minimal Disease Activity Despite the availability of numerous advanced therapies for PsA, there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study https://t.co/OUb3bKo98v https://t.co/FDCBcdyIBm

Polyarteritis Nodosa (PAN): Clinical Features and Outcomes A multinational study of PAN through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years). https://t.co/jNNATtKTxA https://t.co/j5o6qTL2zM

Australian study shows self-reported difficulties w/ ambulation (limited<=1 km) had a higher risk of hip and spinal fractures (32% to 219% more)/ Included 239 000 adults >45 yrs https://t.co/5rIkDOK69u https://t.co/iJ8o0dlGlS

Neonatal Fc receptor mAb (lowers Igs) development: 2021 FDA approved efgartigimod (Vyvgart) for myasthenia gravis 2023 FDA approved rozanolixizumab (Rystiggo) for MG 2023 nipocalimab promising efficacy in RA, Sjogrens, hemolytic anemia, MG INTERESTING? https://t.co/HB1fJet3Bo https://t.co/OBrd2Y3nye

Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, finds research published in the open access journal RMD Open. https://t.co/hMlKxIDvlb https://t.co/eNEMuH4Tdc

Metabolic signature for fibromyalgia? Study of 54 FM & 31 controls w/ Machine learning to identify 13 metabolic markers that predicted FM w/ 79% accuracy; levels of 5-hydroxyindole-3-acetic acid & glutamine correlated w/ fatigue. https://t.co/GBTh7UGn1O https://t.co/jlwVAbdIIF

EGPA: Benralizumab (BEN) or Mepolizumab (MEP) A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA. https://t.co/V0qWQ5nOzc https://t.co/SoOid5HKcV

Behçet’s Syndrome A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches. https://t.co/Yb3R4K9Zwf https://t.co/JAxqZ3FcQz

FDA approves 10th adalimumab biosimilar - called Simlandi (adalimumab-ryvk), from Alvotech and Teva. Unique in that it's the 1st high-concentration, citrate-free & interchangeable ADA biosimilar.https://t.co/Kg7Dqr54dg https://t.co/X25SKggJzN

When Meningitis Strikes Twice Amanda Moyer, MD, presents her poster at RWCS 2024. https://t.co/hO8VkcqCkb https://t.co/9tfKI7dEs9